
Browsing restrictions can be lifted for a fee.
-6.74%
Usana health sciences, inc.
-1.34%
Avg of Sector
-0.31%
S&P500

Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2026Q1 | ||||
| 2026Q2 | ||||
| 2026Q3 | ||||
| 2026Q4 | ||||
| 2027Q1 |
USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products directly in the Asia Pacific, the Americas, and Europe, as well as online. The company has a research collaboration agreement with Beijing University of Chinese Medicine for research in the field of traditional Chinese medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah.
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2025Q4 | |||||||
| 2025Q3 | |||||||
| 2025Q2 | |||||||
| 2025Q1 |
The most recent financial report for Usana health sciences, inc. (USNA) covers the period of 2025Q4 and was published on 2026/01/03. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating USNA's short-term business performance and financial health. For the latest updates on USNA's earnings releases, visit this page regularly.
According to historical valuation range analysis, Usana health sciences, inc. (USNA)'s current price-to-earnings (P/E) ratio is -50.11, placing it in the Overvalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, Usana health sciences, inc. (USNA) reported an Operating Profit of 17.25M with an Operating Margin of 7.63% this period, representing a growth of 110.1% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, Usana health sciences, inc. (USNA) announced revenue of 226.2M, with a Year-Over-Year growth rate of 5.89%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, Usana health sciences, inc. (USNA) held Total Cash and Cash Equivalents of 158.38M, accounting for 0.21 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, Usana health sciences, inc. (USNA) did not achieve the “three margins increasing” benchmark, with a gross margin of 88.77%%, operating margin of 7.63%%, and net margin of -0.78%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess USNA's profit trajectory and future growth potential.
According to the past four quarterly reports, Usana health sciences, inc. (USNA)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.1. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
Usana health sciences, inc. (USNA)'s Free Cash Flow (FCF) for the period is -5.16M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 118.97% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
The latest valuation data shows Usana health sciences, inc. (USNA) has a Price-To-Earnings (PE) ratio of -50.11 and a Price/Earnings-To-Growth (PEG) ratio of 0.69. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.